JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
Cardarine, which is also known as GW-501516 and Endurobol, is a synthetic receptor agonist of PPARδ. It has been well established that PPARδ is a nuclear receptor that regulates gene expression, lipid metabolism and cellular energy generation. Cardarine is extensively used in laboratory research to investigate PPAR regulation and signaling, metabolic implementations and transcriptional control theories.
Originally developed in the 1990s through collaborative research by GlaxoSmithKline and Ligand Pharmaceuticals, Cardarine was explored in preclinical models for its effects on metabolic and cardiovascular pathways. Currently, it is a compound of interest in experimental studies investigating molecular energy regulation, lipid metabolism, and cellular signaling. At Element CRP, Cardarine is supplied exclusively for laboratory, analytical, and educational research purposes and is not intended for human or animal use.
From Pubchem
IUPAC Name:2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acidSynonyms: Endurobol, GW 1516Molecular Formula: C21H18F3NO3S2Molecular Weight: 453.5 g/molCAS Number: 317318-70-0PubChem CID: 9803963
Cardarine (GW501516), a synthetic agonist of PPARδ, is also commonly used in laboratory studies on the control of lipid metabolism and fatty acid oxidation. In vitro and in vivo, PPARδ activation has been reported to enhance the expression of genes implicated in beta-oxidation/energy expenditure and affect lipid accumulation.
In a well-controlled preclinical study, GW501516 was administered to animals at different dose levels, with key panels including lipoproteins, fatty acid oxidation markers and lipid metabolism gene expression. The expression of CPT1, CD36, and ABCA1 increased as well as lipid parameters profile which suggested modulation in peripheral fat utilization under experimental conditions [1,2].
Cardarine is a molecular probe that has been used in laboratory models for energy expenditure and substrate utilization studies. In these systems activation of PPARδ affects mitochondrial biogenesis, fatty acid oxidation and cellular energy homeostasis.
Preclinical studies in murine models demonstrated enhanced endurance and energy output under controlled treadmill or exercise protocols when treated with GW501516 [3]. No clinical data currently supports its use as a performance enhancer in humans.
PPARδ agonists have been utilized in preclinical models to assess glucose metabolism and insulin signaling cascades. In rodent models of experimental hyperglycemia, GW 501516 induced alteration in markers of glucose uptake such as GLUT2 expression in pancreatic tissue. Measurements included fasting glucose equivalents and insulin-signaling pathway activation within each given experimental protocol [4].
Moreover, in vitro fibroblast and tissue cultures, GW 501516 exposure has been investigated with respect to oxidative stress parameters and cells migration dynamics involved in tissue healing processes [5].
In preclinical trials, GW 501516 has been shown to have a influence on neoplastic lesion formation. In a controlled rodent carcinogenesis study higher incidences of proliferative lesions have been observed in colitis-associated colon in association with exposure to the substance. These reports are confined to experimental models and do not provide clinical safety evidence [6].
GW 501516 is still being used as a research tool to study PPARδ-related effects on the transcriptional regulation, lipid metabolism, energy homeostasis and preclinical endpoints of cancer. There is no regulatory approval for use in the clinic and its use is limited to research, including laboratory research, analytical studies and educational research. At Element CRP, GW501516 is provided exclusively for laboratory, analytical, and educational research purposes and is not intended for human or animal use. Only authorized researchers should buy GW501516 for experimental studies.
GW-501516 (cardarine) is a small-molecule selective agonist at the peroxisome proliferator-activated receptor delta (PPAR-d), a nuclear receptor involved in metabolic gene expression regulation. Its structural profile supports reliable behaviour in standard cell culture buffer systems used for nuclear receptor pharmacology research.
Cell-based research with GW-501516 examines PPAR-d binding and downstream transcriptional regulation in skeletal muscle and adipocyte cell models. Functional readouts include PPRE-driven luciferase reporter assays, target gene expression analysis (CPT1, PDK4, ANGPTL4), and comparative pharmacology against other PPAR isoform-selective agonists.
Element CRP supplies this product at 20mg/mL × 30mL. USA-manufactured via chemical synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Pre-mixed liquid solution in 30mL or 60mL bottle with dropper; ready for laboratory use. Store at 15-25°C, away from direct light.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
